Authors' reply

Simple item page
dc.contributor.authorPrice, T.J.
dc.contributor.authorPeeters, M.
dc.contributor.authorRuff, P.
dc.contributor.authorMurugappan, S.
dc.contributor.authorSidhu, R.
dc.date.issued2014
dc.descriptionCorrespondence
dc.description.statementofresponsibilityTimothy J Price, Marc Peeters, Paul Ruff, Swaminathan Murugappan, Roger Sidhu
dc.identifier.citationThe Lancet Oncology, 2014; 15(8):e303-e303
dc.identifier.doi10.1016/S1470-2045(14)70291-8
dc.identifier.issn1470-2045
dc.identifier.issn1474-5488
dc.identifier.orcidPrice, T.J. [0000-0002-3922-2693]
dc.identifier.orcidPeeters, M. [0000-0003-4969-2303]
dc.identifier.urihttp://hdl.handle.net/2440/93646
dc.language.isoen
dc.publisherElsevier
dc.rightsCopyright status unknown
dc.source.urihttps://doi.org/10.1016/s1470-2045(14)70291-8
dc.subjectHumans
dc.subjectColorectal Neoplasms
dc.subjectAntineoplastic Agents
dc.subjectAntibodies, Monoclonal
dc.subjectFemale
dc.subjectMale
dc.subjectAntibodies, Monoclonal, Humanized
dc.titleAuthors' reply
dc.title.alternativeASPECCT: panitumumab versus cetuximab for colorectal cancer – authors' reply
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications